[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.179.146. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
September 9, 2009

Measurement of Serum ProcalcitoninA Step Closer to Tailored Care for Respiratory Infections?

Author Affiliations

Author Affiliations: Department of Emergency Medicine, University of Pittsburgh School of Medicine (Dr Yealy); and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, and Division of General Internal Medicine, University of Pittsburgh Medical Center (Dr Fine), Pittsburgh, Pennsylvania.

JAMA. 2009;302(10):1115-1116. doi:10.1001/jama.2009.1318

The advent of antibiotics led to dramatic reductions in mortality and medical complications from bacterial respiratory tract infections.1 Although the armamentarium of diagnostic and therapeutic approaches has increased exponentially since that time, the effect of these advances on patient outcomes is less dramatic. Nevertheless, the goal of care remains constant: to match the patient's illness with a treatment approach that optimizes recovery while causing no harm. Harm exists in at least 2 forms: patient-specific, from an adverse event due to a diagnostic test or a treatment,2 and population-based, from the development of bacterial resistance promoted by the misuse or overuse of antibiotics.1,3

First Page Preview View Large
First page PDF preview
First page PDF preview
×